

The biology and therapeutic targeting of the proprotein

Nature Reviews Drug Discovery

11, 367-383

DOI: [10.1038/nrd3699](https://doi.org/10.1038/nrd3699)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein. <i>Viruses</i> , 2012, 4, 1011-1033.	1.5	1,086
2	PCSK9, a novel target for lowering LDL cholesterol: promise and progress. <i>Clinical Lipidology</i> , 2012, 7, 611-615.	0.4	2
3	PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials. <i>Clinical Lipidology</i> , 2012, 7, 621-640.	0.4	16
4	Loss- and Gain-of-function PCSK9 Variants. <i>Journal of Biological Chemistry</i> , 2012, 287, 33745-33755.	1.6	71
5	The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway. <i>Journal of Biological Chemistry</i> , 2012, 287, 43492-43501.	1.6	62
6	Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases. <i>Scientifica</i> , 2012, 2012, 1-21.	0.6	10
7	Highlighting the future potential of PCSK9-targeted therapeutics. <i>Clinical Lipidology</i> , 2012, 7, 599-601.	0.4	3
8	Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2012, 14, 721-731.	1.3	20
9	The PCSK9 decade. <i>Journal of Lipid Research</i> , 2012, 53, 2515-2524.	2.0	355
10	Into the future: diversifying lipid management. <i>Lancet, The</i> , 2012, 380, 1971-1974.	6.3	6
11	Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver. <i>Neoplasia</i> , 2012, 14, 1122-IN5.	2.3	94
12	The Multi-Leu Peptide Inhibitor Discriminates Between PACE4 and Furin And Exhibits Antiproliferative Effects On Prostate Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10501-10511.	2.9	49
13	My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. <i>Biochemistry and Cell Biology</i> , 2012, 90, 750-768.	0.9	18
14	The Role of Proprotein Convertases in Animal Models of Skin Carcinogenesis. <i>Colloquium Series on Protein Activation and Cancer</i> , 2012, 1, 1-60.	0.0	0
15	Antibody-enabled small-molecule drug discovery. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 519-525.	21.5	63
16	Opposite Roles of Furin and PC5A in N-Cadherin Processing. <i>Neoplasia</i> , 2012, 14, 880-IN3.	2.3	23
17	Role of Proprotein Convertases in Prostate Cancer Progression. <i>Neoplasia</i> , 2012, 14, 1032-IN6.	2.3	52
18	Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. <i>Lipids in Health and Disease</i> , 2013, 12, 70.	1.2	50

#	ARTICLE	IF	CITATIONS
19	Activatable Oligomerizable Imaging Agents for Photoacoustic Imaging of Furin-Like Activity in Living Subjects. <i>Journal of the American Chemical Society</i> , 2013, 135, 11015-11022.	6.6	196
20	Proteolytic cleavage of LEDA-1/PIANP by furin-like proprotein convertases precedes its plasma membrane localization. <i>Biochemical and Biophysical Research Communications</i> , 2013, 434, 22-27.	1.0	5
21	Mutation in Spike Protein Cleavage Site and Pathogenesis of Feline Coronavirus. <i>Emerging Infectious Diseases</i> , 2013, 19, 1066-1073.	2.0	146
22	Small-molecule inhibitors of SREBP activation – potential for new treatment of metabolic disorders. <i>MedChemComm</i> , 2013, 4, 1422.	3.5	10
23	Linking melanism to brain development: expression of a melanism-related gene in barn owl feather follicles covaries with sleep ontogeny. <i>Frontiers in Zoology</i> , 2013, 10, 42.	0.9	61
24	Pleiotropy in the melanocortin system: expression levels of this system are associated with melanogenesis and pigmentation in the tawny owl (<i>Strix aluco</i>). <i>Molecular Ecology</i> , 2013, 22, 4915-4930.	2.0	50
25	The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies. <i>International Journal of Cardiology</i> , 2013, 168, 1811-1818.	0.8	33
26	Implication of the proprotein convertases in iron homeostasis: Proprotein convertase 7 sheds human transferrin receptor 1 and furin activates hepcidin. <i>Hepatology</i> , 2013, 57, 2514-2524.	3.6	57
27	The next generation of novel low-density lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors. <i>Pharmacological Research</i> , 2013, 73, 27-34.	3.1	17
28	Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1401-1408.	1.2	241
29	Dauer-Specific Dendrite Arborization in <i>C.Âlegans</i> Is Regulated by KPC-1/Furin. <i>Current Biology</i> , 2013, 23, 1527-1535.	1.8	91
30	Platelet-derived growth factors and their receptors: Structural and functional perspectives. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 2176-2186.	1.1	159
31	Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression. <i>Journal of Lipid Research</i> , 2013, 54, 2400-2409.	2.0	29
32	Substrate Cleavage Profiling Suggests a Distinct Function of <i>Bacteroides fragilis</i> Metalloproteinases (Fragilysin and Metalloproteinase II) at the Microbiome-Inflammation-Cancer Interface. <i>Journal of Biological Chemistry</i> , 2013, 288, 34956-34967.	1.6	25
33	Proprotein convertases in high-density lipoprotein metabolism. <i>Biomarker Research</i> , 2013, 1, 27.	2.8	24
34	Relative expression of proprotein convertases in rat ovaries during pregnancy. <i>Journal of Ovarian Research</i> , 2013, 6, 91.	1.3	4
35	Anti-PCSK9 therapies for the treatment of hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 429-435.	1.4	45
36	Exploring mechanisms of FGF signalling through the lens of structural biology. <i>Nature Reviews Molecular Cell Biology</i> , 2013, 14, 166-180.	16.1	449

#	ARTICLE	IF	CITATIONS
37	Enhanced UV-Induced Skin Carcinogenesis in Transgenic Mice Overexpressing Proprotein Convertases. <i>Neoplasia</i> , 2013, 15, 169-179.	2.3	14
38	Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 593-600.e12.	1.5	210
39	Proprotein convertases Subtilisin/Kexin Type 9, an enzyme turned escort protein: Hepatic and extra hepatic functions (ç¬9âžã%èç™1/2è1/2æÉ...řâ€”æž`è%æ°řâ€ç/èç201/2é...řKí		
40	Viral envelope glycoprotein processing by proprotein convertases. <i>Antiviral Research</i> , 2013, 99, 49-60.	1.9	22
41	How the Prohormone Theory Solved Two Important Controversies in Hormonal and Neural Peptide Biosynthesis. <i>Frontiers in Endocrinology</i> , 2013, 4, 148.	1.5	11
42	Structural and Functional Analysis of the CspB Protease Required for Clostridium Spore Germination. <i>PLoS Pathogens</i> , 2013, 9, e1003165.	2.1	99
43	Expanding Proteostasis by Membrane Trafficking Networks. <i>Cold Spring Harbor Perspectives in Biology</i> , 2013, 5, a013383-a013383.	2.3	34
44	The Malarial Serine Protease SUB1 Plays an Essential Role in Parasite Liver Stage Development. <i>PLoS Pathogens</i> , 2013, 9, e1003811.	2.1	34
45	Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor. <i>Circulation</i> , 2013, 127, 2403-2413.	1.6	169
46	PCSK9 inhibitors. <i>Current Opinion in Lipidology</i> , 2013, 24, 251-258.	1.2	39
47	The Evolving Field of Human Papillomavirus Receptor Research: a Review of Binding and Entry. <i>Journal of Virology</i> , 2013, 87, 6062-6072.	1.5	148
48	The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1135.	2.0	40
49	Engineering of $\hat{A}1$ -antitrypsin variants with improved specificity for the proprotein convertase furin using site-directed random mutagenesis. <i>Protein Engineering, Design and Selection</i> , 2013, 26, 123-131.	1.0	9
50	Proprotein Convertase Subtilisin/Kexin Type 7 (PCSK7) Is Essential for the Zebrafish Development and Bioavailability of Transforming Growth Factor \hat{I}^21a (TGF \hat{I}^21a)*. <i>Journal of Biological Chemistry</i> , 2013, 288, 36610-36623.	1.6	14
51	Furin Is the Primary in Vivo Convertase of Angiopoietin-like 3 and Endothelial Lipase in Hepatocytes. <i>Journal of Biological Chemistry</i> , 2013, 288, 26410-26418.	1.6	43
52	Differential Recognition of Old World and New World Arenavirus Envelope Glycoproteins by Subtilisin Kexin Isozyme 1 (SKI-1)/Site 1 Protease (S1P). <i>Journal of Virology</i> , 2013, 87, 6406-6414.	1.5	18
53	Treadmill Exercise Training Modulates Hepatic Cholesterol Metabolism and Circulating PCSK9 Concentration in High-Fat-Fed Mice. <i>Journal of Lipids</i> , 2013, 2013, 1-9.	1.9	26
54	Profiling of Atherosclerotic Lesions by Gene and Tissue Microarrays Reveals PCSK6 as a Novel Protease in Unstable Carotid Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2432-2443.	1.1	84

#	ARTICLE	IF	CITATIONS
55	The Polybasic Insertion in Autotaxin $\hat{\pm}$ Confers Specific Binding to Heparin and Cell Surface Heparan Sulfate Proteoglycans. <i>Journal of Biological Chemistry</i> , 2013, 288, 510-519.	1.6	48
56	The Multifaceted Proprotein Convertases: Their Unique, Redundant, Complementary, and Opposite Functions. <i>Journal of Biological Chemistry</i> , 2013, 288, 21473-21481.	1.6	151
57	Disruption of the expression of the proprotein convertase PC7 reduces BDNF production and affects learning and memory in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17362-17367.	3.3	74
58	Identification of Serpin Determinants of Specificity and Selectivity for Furin Inhibition through Studies of $\hat{\pm}$ 1PDX ($\hat{\pm}$ 1-Protease Inhibitor Portland)-Serpin B8 and Furin Active-site Loop Chimeras. <i>Journal of Biological Chemistry</i> , 2013, 288, 21802-21814.	1.6	7
59	Propeptides of eukaryotic proteases encode histidines to exploit organelle pH for regulation. <i>FASEB Journal</i> , 2013, 27, 2939-2945.	0.2	2
62	ENaC Regulation by Proteases and Shear Stress. <i>Current Molecular Pharmacology</i> , 2013, 6, 28-34.	0.7	33
63	In utero Measurement of Heart Rate in Mouse by Noninvasive M-mode Echocardiography. <i>Journal of Visualized Experiments</i> , 2013, , e50994.	0.2	4
64	Proprotein Convertase Subtilisin/Kexin Type 3 Promotes Adipose Tissue-Driven Macrophage Chemotaxis and Is Increased in Obesity. <i>PLoS ONE</i> , 2013, 8, e70542.	1.1	11
65	Modulation of Protease Activated Receptor 1 Influences Human Metapneumovirus Disease Severity in a Mouse Model. <i>PLoS ONE</i> , 2013, 8, e72529.	1.1	33
66	A Fully Human Inhibitory Monoclonal Antibody to the Wnt Receptor RYK. <i>PLoS ONE</i> , 2013, 8, e75447.	1.1	22
67	Small Molecule Proprotein Convertase Inhibitors for Inhibition of Embryo Implantation. <i>PLoS ONE</i> , 2013, 8, e81380.	1.1	3
68	Mutation Screening and Array Comparative Genomic Hybridization Using a 180K Oligonucleotide Array in VACTERL Association. <i>PLoS ONE</i> , 2014, 9, e85313.	1.1	22
69	Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia. <i>Medical Principles and Practice</i> , 2014, 23, 99-111.	1.1	49
70	Zymogen Activation and Subcellular Activity of Subtilisin Kexin Isozyme 1/Site 1 Protease. <i>Journal of Biological Chemistry</i> , 2014, 289, 35743-35756.	1.6	18
71	The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Active Site and Cleavage Sequence Differentially Regulate Protein Secretion from Proteolysis. <i>Journal of Biological Chemistry</i> , 2014, 289, 29030-29043.	1.6	31
72	A Smallâ€Molecule FRET Reporter for the Realâ€Time Visualization of Cellâ€Surface Proteolytic Enzyme Functions. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 14357-14362.	7.2	63
73	Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. <i>Journal of Lipid Research</i> , 2014, 55, 266-275.	2.0	24
74	PACE4-Based Molecular Targeting of Prostate Cancer Using an Engineered ^{64}Cu -Radiolabeled Peptide Inhibitor. <i>Neoplasia</i> , 2014, 16, 634-643.	2.3	14

#	ARTICLE	IF	CITATIONS
75	The Proprotein Convertase KPC-1/Furin Controls Branching and Self-avoidance of Sensory Dendrites in <i>Caenorhabditis elegans</i> . <i>PLoS Genetics</i> , 2014, 10, e1004657.	1.5	42
76	Human iPSC Neurons Display Activity-Dependent Neurotransmitter Secretion: Aberrant Catecholamine Levels in Schizophrenia Neurons. <i>Stem Cell Reports</i> , 2014, 3, 531-538.	2.3	97
77	Is there a link between proprotein convertase PC7 activity and human lipid homeostasis?. <i>FEBS Open Bio</i> , 2014, 4, 741-745.	1.0	9
78	Fibroblast growth factor 23. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 203-227.	0.8	53
79	Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1137-1144.	0.6	15
80	Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. <i>Lipids in Health and Disease</i> , 2014, 13, 188.	1.2	24
81	X-ray Structures of Human Furin in Complex with Competitive Inhibitors. <i>ACS Chemical Biology</i> , 2014, 9, 1113-1118.	1.6	69
82	Design, Synthesis, and Structure-Activity Relationship Studies of a Potent PACE4 Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 98-109.	2.9	30
83	Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. <i>Lipids in Health and Disease</i> , 2014, 13, 35.	1.2	15
85	Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. <i>Human Molecular Genetics</i> , 2014, 23, 3883-3890.	1.4	50
86	Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor. <i>Journal of Biological Chemistry</i> , 2014, 289, 942-955.	1.6	126
87	Therapeutic modulation of Notch signalling "are we there yet?". <i>Nature Reviews Drug Discovery</i> , 2014, 13, 357-378.	21.5	413
88	Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis. <i>Carcinogenesis</i> , 2014, 35, 528-536.	1.3	22
89	PCSK9: From discovery to therapeutic applications. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 58-66.	0.7	83
90	HPV16 infection of HaCaTs is dependent on $\alpha 4$ integrin, and $\beta 6$ integrin processing. <i>Virology</i> , 2014, 449, 45-52.	1.1	33
91	Emerging drugs for hyperlipidaemia: an update. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 471-488.	1.0	5
92	Pericellular proteolysis in cancer. <i>Genes and Development</i> , 2014, 28, 2331-2347.	2.7	154
93	Opioid Receptor Function Is Regulated by Post-endocytic Peptide Processing. <i>Journal of Biological Chemistry</i> , 2014, 289, 19613-19626.	1.6	18

#	ARTICLE	IF	CITATIONS
94	Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. <i>Journal of Lipid Research</i> , 2014, 55, 2103-2112.	2.0	165
95	Lipid pharmacotherapy for treatment of atherosclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1119-1125.	0.9	13
96	Neuroendocrinology of the hair follicle: principles and clinical perspectives. <i>Trends in Molecular Medicine</i> , 2014, 20, 559-570.	3.5	104
97	LDL cholesterol: controversies and future therapeutic directions. <i>Lancet, The</i> , 2014, 384, 607-617.	6.3	229
98	Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15214-15219.	3.3	576
99	Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for Cathepsin S. <i>Nature Cell Biology</i> , 2014, 16, 876-888.	4.6	300
100	An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 57-63.	2.3	42
101	A novel Plasmodium-specific prodomain fold regulates the malaria drug target SUB1 subtilase. <i>Nature Communications</i> , 2014, 5, 4833.	5.8	20
102	PCSK9. <i>Circulation Research</i> , 2014, 114, 1022-1036.	2.0	495
103	Worm peptidomics. <i>EuPA Open Proteomics</i> , 2014, 3, 280-290.	2.5	17
104	Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. <i>Translational Oncology</i> , 2014, 7, 410-419.	1.7	30
105	Regulation of TGF β 2 and related signals by precursor processing. <i>Seminars in Cell and Developmental Biology</i> , 2014, 32, 85-97.	2.3	78
106	Annexin A2 Reduces PCSK9 Protein Levels via a Translational Mechanism and Interacts with the M1 and M2 Domains of PCSK9. <i>Journal of Biological Chemistry</i> , 2014, 289, 17732-17746.	1.6	40
107	Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 412-424.	1.3	107
109	Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. <i>Journal of Clinical Lipidology</i> , 2015, 9, 420-421.	0.6	0
110	17 β -Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells. <i>FEBS Journal</i> , 2015, 282, 2682-2696.	2.2	14
111	The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. <i>Global Cardiology Science & Practice</i> , 2015, 2015, 59.	0.3	2
112	PACE4 (PCSK6): another proprotein convertase link to iron homeostasis?. <i>Haematologica</i> , 2015, 100, e377-e377.	1.7	22

#	ARTICLE	IF	CITATIONS
113	Effect of iron overload on furin expression in wild-type and β^0 -thalassemic mice. <i>Toxicology Reports</i> , 2015, 2, 415-422.	1.6	9
114	Engineering a Constrained Peptidic Scaffold towards Potent and Selective Furin Inhibitors. <i>ChemBioChem</i> , 2015, 16, 2441-2444.	1.3	26
115	Novel Furin Inhibitors with Potent Anti-infectious Activity. <i>ChemMedChem</i> , 2015, 10, 1218-1231.	1.6	64
116	Regulation of HIF-1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cells. <i>Molecular Carcinogenesis</i> , 2015, 54, 698-706.	1.3	9
117	Proprotein convertases in atherogenesis. <i>Current Opinion in Lipidology</i> , 2015, 26, 338-344.	1.2	9
118	Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	5
119	Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter of FURIN Is Not Prognostic to Colon Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	3
120	PACE4 regulates apoptosis in human prostate cancer cells via endoplasmic reticulum stress and mitochondrial signaling pathways. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5911.	2.0	10
121	Synergy of Omeprazole and Praziquantel In Vitro Treatment against <i>Schistosoma mansoni</i> Adult Worms. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004086.	1.3	17
122	Cleavage of a Neuroinvasive Human Respiratory Virus Spike Glycoprotein by Proprotein Convertases Modulates Neurovirulence and Virus Spread within the Central Nervous System. <i>PLoS Pathogens</i> , 2015, 11, e1005261.	2.1	62
123	Liver-Specific Inactivation of the Proprotein Convertase FURIN Leads to Increased Hepatocellular Carcinoma Growth. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	15
124	Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9. <i>Protein Engineering, Design and Selection</i> , 2015, 28, 117-125.	1.0	6
125	Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays. <i>Biochemical Pharmacology</i> , 2015, 96, 107-118.	2.0	13
126	Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. <i>Postgraduate Medicine</i> , 2015, 127, 125-132.	0.9	14
127	Influenza virus activating host proteases: Identification, localization and inhibitors as potential therapeutics. <i>European Journal of Cell Biology</i> , 2015, 94, 375-383.	1.6	73
128	Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells. <i>Antiviral Research</i> , 2015, 120, 89-100.	1.9	29
129	Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1589-1596.	1.1	74
130	Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. <i>International Journal of Neuroscience</i> , 2016, 126, 1-6.	0.8	22

#	ARTICLE	IF	CITATIONS
131	Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 426-433.	1.1	25
132	Neuropeptidomics Mass Spectrometry Reveals Signaling Networks Generated by Distinct Protease Pathways in Human Systems. <i>Journal of the American Society for Mass Spectrometry</i> , 2015, 26, 1970-1980.	1.2	23
133	Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 287-298.	1.4	6
134	MBTPS1/SKI-1/S1P proprotein convertase is required for ECM signaling and axial elongation during somitogenesis and vertebral development. <i>Human Molecular Genetics</i> , 2015, 24, 2884-2898.	1.4	23
135	LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): Design, synthesis and biochemical evaluation. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 890-907.	2.6	34
136	Therapeutic uses of furin and its inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 379-396.	2.4	70
137	The Paired Basic Amino Acid-cleaving Enzyme 4 (PACE4) Is Involved in the Maturation of Insulin Receptor Isoform B. <i>Journal of Biological Chemistry</i> , 2015, 290, 2812-2821.	1.6	20
138	Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2638-2651.	1.2	156
139	Determination of Histidine δ Values in the Propeptides of Furin and Proprotein Convertase 1/3 Using Histidine Hydrogen Deuterium Exchange Mass Spectrometry. <i>Analytical Chemistry</i> , 2015, 87, 7909-7917.	3.2	10
140	Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. <i>Journal of Biological Chemistry</i> , 2015, 290, 18609-18620.	1.6	47
141	The Proprotein Convertase Subtilisin/Kexin FurinA Regulates Zebrafish Host Response against <i>Mycobacterium marinum</i> . <i>Infection and Immunity</i> , 2015, 83, 1431-1442.	1.0	15
142	Novel Lipid-Lowering Agents. <i>Contemporary Endocrinology</i> , 2015, , 499-519.	0.3	0
143	Prodomain Removal Enables Neto to Stabilize Glutamate Receptors at the <i>Drosophila</i> Neuromuscular Junction. <i>PLoS Genetics</i> , 2015, 11, e1004988.	1.5	14
144	Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 213-219.	1.0	15
145	Enediynyl peptides and iso-coumarinyl methyl sulfones as inhibitors of proprotein convertases PCSK8/SKI-1/S1P and PCSK4/PC4: Design, synthesis and biological evaluations. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2225-2237.	1.0	10
146	A genome-wide expression quantitative trait loci analysis of proprotein convertase subtilisin/kexin enzymes identifies a novel regulatory gene variant for FURIN expression and blood pressure. <i>Human Genetics</i> , 2015, 134, 627-636.	1.8	29
147	Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms. <i>Journal of Translational Medicine</i> , 2015, 13, 87.	1.8	12
148	Protein Folding Mediated by an Intramolecular Chaperone: Energy Landscape for Unimolecular Pro-Subtilisin E Maturation. <i>Advances in Bioscience and Biotechnology (Print)</i> , 2015, 06, 73-88.	0.3	4

#	ARTICLE	IF	CITATIONS
149	Structure of bone morphogenetic protein 9 procomplex. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3710-3715.	3.3	100
150	An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1347-1359.	1.8	234
151	Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. Journal of Lipid Research, 2015, 56, 463-469.	2.0	70
152	PC7 and the related proteases Furin and Pace4 regulate E-cadherin function during blastocyst formation. Journal of Cell Biology, 2015, 210, 1185-1197.	2.3	20
153	Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. Journal of Biological Chemistry, 2015, 290, 23385-23400.	1.6	22
154	The RYK Receptor Family. , 2015, , 685-741.		6
155	PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice. Journal of Lipid Research, 2015, 56, 2133-2142.	2.0	45
156	Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (<scp>PCSK9</scp>) concentrations: a systematic review and meta-analysis of clinical trials. Diabetes, Obesity and Metabolism, 2015, 17, 1042-1055.	2.2	77
157	PCSK6-mediated corin activation is essential for normal blood pressure. Nature Medicine, 2015, 21, 1048-1053.	15.2	117
158	Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. Clinical Therapeutics, 2015, 37, 1945-1954.e6.	1.1	24
159	Selection and characterization of human PCSK9 antibody from phage displayed antibody library. Biochemical and Biophysical Research Communications, 2015, 463, 712-718.	1.0	6
160	Neuroinflammation-Induced Interactions between Protease-Activated Receptor 1 and Proprotein Convertases in HIV-Associated Neurocognitive Disorder. Molecular and Cellular Biology, 2015, 35, 3684-3700.	1.1	29
161	The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype. Metabolism: Clinical and Experimental, 2015, 64, 1541-1547.	1.5	10
162	A Dual Role for the Nonreceptor Tyrosine Kinase Pyk2 during the Intracellular Trafficking of Human Papillomavirus 16. Journal of Virology, 2015, 89, 9103-9114.	1.5	15
163	An evaluation of alirocumab for the treatment of hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2015, 13, 1307-1323.	0.6	21
164	Characterization and expression of proprotein convertases in CHO cells: Efficient proteolytic maturation of human bone morphogenetic protein-7. Biotechnology and Bioengineering, 2015, 112, 560-568.	1.7	10
165	Inhibition of Proprotein Convertases Abrogates Processing of the Middle Eastern Respiratory Syndrome Coronavirus Spike Protein in Infected Cells but Does Not Reduce Viral Infectivity. Journal of Infectious Diseases, 2015, 211, 889-897.	1.9	34
166	Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus Research, 2015, 202, 120-134.	1.1	752

#	ARTICLE	IF	CITATIONS
167	Asymmetry of the Endogenous Opioid System in the Human Anterior Cingulate: a Putative Molecular Basis for Lateralization of Emotions and Pain. <i>Cerebral Cortex</i> , 2015, 25, 97-108.	1.6	41
168	The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion. <i>PLoS ONE</i> , 2016, 11, e0161396.	1.1	16
169	Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models. <i>JCI Insight</i> , 2016, 1, e89371.	2.3	28
170	PACE4 regulates apoptosis in human pancreatic cancer Panc-1 cells via the mitochondrial signaling pathway. <i>Molecular Medicine Reports</i> , 2016, 14, 5205-5210.	1.1	4
171	Atherosclerosis and Coronary Artery Disease. , 2016, , 3-24.		8
172	60 YEARS OF POMC: From the prohormone theory to pro-opiomelanocortin and to proprotein convertases (PCSK1 to PCSK9). <i>Journal of Molecular Endocrinology</i> , 2016, 56, T49-T62.	1.1	43
173	New developments in proprotein convertase subtilisinâ€“kexin 9's biology and clinical implications. <i>Current Opinion in Lipidology</i> , 2016, 27, 274-281.	1.2	47
174	Comparison of two lowâ€“density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia. <i>Journal of Clinical Apheresis</i> , 2016, 31, 359-367.	0.7	17
175	Nicotine regulates cocaineâ€“amphetamineâ€“Regulated Transcript (Cart) in the mesocorticolimbic system. <i>Synapse</i> , 2016, 70, 283-292.	0.6	8
176	Novel Insights into Structureâ€“Activity Relationships of Nâ€“Terminally Modified PACE4 Inhibitors. <i>ChemMedChem</i> , 2016, 11, 289-301.	1.6	12
177	Regulated Proteolysis of Signaling Molecules: The Proprotein Convertases. , 2016, , 555-567.		2
178	Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors. <i>Current Opinion in Cardiology</i> , 2016, 31, 644-653.	0.8	4
179	Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. <i>American Heart Journal</i> , 2016, 178, 135-144.	1.2	58
180	Monoclonal Antibodies for Lipid Management. <i>Current Atherosclerosis Reports</i> , 2016, 18, 39.	2.0	6
181	Liver fat accumulation is associated with circulating PCSK9. <i>Annals of Medicine</i> , 2016, 48, 384-391.	1.5	119
182	PCSK9 inhibitors in the prevention of cardiovascular disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 405-419.	1.0	26
183	Monoclonal antibodies targeting PCSK9 and the search for prolonged duration of effect. <i>European Heart Journal</i> , 2016, 37, 1370-1372.	1.0	1
184	Detergent-Assisted Glycoprotein Capture: A Versatile Tool for In-Depth N-Glycoproteome Analysis. <i>Journal of Proteome Research</i> , 2016, 15, 2080-2086.	1.8	13

#	ARTICLE	IF	CITATIONS
185	Enhanced Proteolytic Processing of Recombinant Human Coagulation Factor VIII B-Domain Variants by Recombinant Furins. <i>Molecular Biotechnology</i> , 2016, 58, 404-414.	1.3	3
186	Mechanism of Folding and Activation of Subtilisin Kexin Isozyme-1 (SKI-1)/Site-1 Protease (S1P). <i>Journal of Biological Chemistry</i> , 2016, 291, 2055-2066.	1.6	13
187	Insulin-like growth factor 2 rescues aging-related memory loss in rats. <i>Neurobiology of Aging</i> , 2016, 44, 9-21.	1.5	37
188	Disrupting the PCSK9/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 9736-9740.	1.5	42
189	A SEMA3E mutant resistant to cleavage by furins (UNCL-SEMA3E) inhibits choroidal neovascularization. <i>Experimental Eye Research</i> , 2016, 153, 186-194.	1.2	6
190	Proprotein Convertase Processing Enhances Peroxidase Activity to Reinforce Collagen IV. <i>Journal of Biological Chemistry</i> , 2016, 291, 24009-24016.	1.6	19
191	A review of PCSK9 inhibition and its effects beyond LDL receptors. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1073-1080.	0.6	39
192	Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11196-11201.	3.3	73
193	Bunyamwera orthobunyavirus glycoprotein precursor is processed by cellular signal peptidase and signal peptide peptidase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 8825-8830.	3.3	40
194	Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 222, 119-129.	0.8	23
195	Structural Biology and Evolution of the TGF- β Family. <i>Cold Spring Harbor Perspectives in Biology</i> , 2016, 8, a022103.	2.3	267
196	In Vitro Assays for the Discovery of PCSK9 Autoprocessing Inhibitors. <i>Journal of Biomolecular Screening</i> , 2016, 21, 1034-1041.	2.6	2
197	Secreted factors from adipose tissue-derived mesenchymal stem cells suppress oxygen/glucose deprivation-induced cardiomyocyte cell death via furin/PCSK-like enzyme activity. <i>Biochemistry and Biophysics Reports</i> , 2016, 7, 266-272.	0.7	3
198	Oocyte-somatic cell interactions in the human ovary—novel role of bone morphogenetic proteins and growth differentiation factors. <i>Human Reproduction Update</i> , 2016, 23, 1-18.	5.2	212
199	The structure of a furin-antibody complex explains non-competitive inhibition by steric exclusion of substrate conformers. <i>Scientific Reports</i> , 2016, 6, 34303.	1.6	18
200	Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells. <i>Scientific Reports</i> , 2016, 6, 29931.	1.6	69
202	ASAP: a machine learning framework for local protein properties. <i>Database: the Journal of Biological Databases and Curation</i> , 2016, 2016, baw133.	1.4	19
203	Proprotein convertase subtilisin kexin type 9 inhibitors. <i>Current Opinion in Lipidology</i> , 2016, 27, 597-604.	1.2	11

#	ARTICLE	IF	CITATIONS
204	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. <i>Journal of Biological Chemistry</i> , 2016, 291, 16659-16671.	1.6	28
205	PCSK9 and Lipoprotein(a). <i>Circulation Research</i> , 2016, 119, 3-6.	2.0	5
206	PCSK1 Mutations and Human Endocrinopathies: From Obesity to Gastrointestinal Disorders. <i>Endocrine Reviews</i> , 2016, 37, 347-371.	8.9	113
207	PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions. <i>Hellenic Journal of Cardiology</i> , 2016, 57, 86-91.	0.4	19
208	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. <i>Circulation</i> , 2016, 133, 2459-2502.	1.6	766
209	Reducing Vascular Calcification by Anti-IL-1 β Monoclonal Antibody in a Mouse Model of Familial Hypercholesterolemia. <i>Angiology</i> , 2016, 67, 157-167.	0.8	44
210	Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans. <i>Science Translational Medicine</i> , 2016, 8, 323ra12.	5.8	27
211	Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. <i>Journal of Biological Chemistry</i> , 2016, 291, 3508-3519.	1.6	93
212	Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. <i>European Heart Journal</i> , 2016, 37, 1720-1722.	1.0	188
213	Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 59-71.	2.3	10
214	Deletion of Mbtps1 (Pcsk8, S1p, Ski-1) Gene in Osteocytes Stimulates Soleus Muscle Regeneration and Increased Size and Contractile Force with Age. <i>Journal of Biological Chemistry</i> , 2016, 291, 4308-4322.	1.6	42
215	Characterization and comparison of proteomes of albino sea cucumber <i>Apostichopus japonicus</i> (Selenka) by iTRAQ analysis. <i>Fish and Shellfish Immunology</i> , 2016, 51, 229-239.	1.6	16
216	Proteases decode the extracellular matrix cryptome. <i>Biochimie</i> , 2016, 122, 300-313.	1.3	63
217	Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. <i>European Heart Journal</i> , 2016, 37, 554-560.	1.0	80
218	Effects of Hedan Tablet (è·ä,1ç%o†) on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study. <i>Chinese Journal of Integrative Medicine</i> , 2016, 22, 660-665.	0.7	5
219	PCSK9 and diabetes: is there a link?. <i>Drug Discovery Today</i> , 2017, 22, 883-895.	3.2	39
220	Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy. <i>Canadian Journal of Cardiology</i> , 2017, 33, 872-882.	0.8	34
221	Proprotein convertases generate a highly functional heterodimeric form of thymic stromal lymphopoietin in humans. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1559-1567.e8.	1.5	27

#	ARTICLE	IF	CITATIONS
222	Bococizumab for the treatment of hypercholesterolaemia. Expert Opinion on Biological Therapy, 2017, 17, 237-243.	1.4	20
223	Prohormone convertase 7 is necessary for the normal processing of cholecystokinin in mouse brain. Biochemical and Biophysical Research Communications, 2017, 482, 1190-1193.	1.0	2
224	Treatment with the natural <scp>FXR</scp> agonist chenodeoxycholic acid reduces clearance of plasma <scp>LDL</scp> whilst decreasing circulating <scp>PCSK</scp>9, lipoprotein(a) and apolipoprotein Câ€œ<scp>III</scp>. Journal of Internal Medicine, 2017, 281, 575-585.	2.7	52
225	Limitations of cholesterol lowering with PCSK9 inhibitors. Lancet Diabetes and Endocrinology, the, 2017, 5, 241-243.	5.5	4
226	Investigations on the hypocholesterolaemic activity of LILPKHSDAD and LTFPGSAED, two peptides from lupin Î²-conglutin: Focus on LDLR and PCSK9 pathways. Journal of Functional Foods, 2017, 32, 1-8.	1.6	49
227	PCSK9 regulates the chemokine receptor CCR2 on monocytes. Biochemical and Biophysical Research Communications, 2017, 485, 312-318.	1.0	36
228	Selection of DNA aptamers with two modified bases. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2898-2903.	3.3	157
229	PCSK9 targets important for lipid metabolism. Clinical Research in Cardiology Supplements, 2017, 12, 2-11.	2.0	46
230	Structural Studies Revealed Active Site Distortions of Human Furin by a Small Molecule Inhibitor. ACS Chemical Biology, 2017, 12, 1211-1216.	1.6	34
231	RNA sequencing for global gene expression associated with muscle growth in a single male modern broiler line compared to a foundational Barred Plymouth Rock chicken line. BMC Genomics, 2017, 18, 82.	1.2	51
232	PCSK9 as a therapeutic target for cardiovascular disease. Experimental and Therapeutic Medicine, 2017, 13, 810-814.	0.8	15
233	Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease. Basic Research in Cardiology, 2017, 112, 32.	2.5	66
234	Thrombin activation of protein C requires prior processing by a liver proprotein convertase. Journal of Biological Chemistry, 2017, 292, 10564-10573.	1.6	10
235	Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations. European Journal of Cell Biology, 2017, 96, 476-485.	1.6	7
236	Proprotein convertase inhibition: Paralyzing the cellâ€™s master switches. Biochemical Pharmacology, 2017, 140, 8-15.	2.0	35
237	Proprotein convertase inhibition promotes ciliated cell differentiation - a potential mechanism for the inhibition of Notch1 signalling by decanoyl-RVKR-chloromethylketone. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 2667-2680.	1.3	9
238	Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis, 2017, 256, 1-6.	0.4	98
239	Site-1 protease is required for the generation of soluble (pro)renin receptor. Journal of Biochemistry, 2017, 161, 369-379.	0.9	74

#	ARTICLE	IF	CITATIONS
240	PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 1993-1999.	0.8	39
241	PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression. <i>European Journal of Cell Biology</i> , 2017, 96, 469-475.	1.6	14
242	Regulation of PCSK9 by nutraceuticals. <i>Pharmacological Research</i> , 2017, 120, 157-169.	3.1	89
243	The proprotein convertase furin in tumour progression. <i>International Journal of Cancer</i> , 2017, 141, 654-663.	2.3	112
244	Elongated and Shortened Peptidomimetic Inhibitors of the Proprotein Convertase Furin. <i>ChemMedChem</i> , 2017, 12, 613-620.	1.6	16
245	Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 712-721.	2.5	34
246	siRNA-mediated inhibition of SREBP cleavage-activating protein reduces dyslipidemia in spontaneously dysmetabolic rhesus monkeys. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 202-212.	1.5	8
247	Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2732-2744.	2.9	9
248	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	13.9	307
249	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
250	The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. <i>Pharmacological Reviews</i> , 2017, 69, 33-52.	7.1	90
251	Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 785-786.	3.6	8
252	PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer. <i>Cancer Research</i> , 2017, 77, 6863-6879.	0.4	58
253	A ratiometric electrochemical strategy for sensitive determination of Furin activity based on dual signal amplification and antifouling nanosurfaces. <i>Analyst, The</i> , 2017, 142, 4215-4220.	1.7	18
254	Optimization of Substrate-Analogue Furin Inhibitors. <i>ChemMedChem</i> , 2017, 12, 1953-1968.	1.6	28
255	Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 848-856.	3.6	53
256	TGF- β -induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche. <i>Blood</i> , 2017, 130, 2283-2294.	0.6	29
257	Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3. <i>ChemMedChem</i> , 2017, 12, 1169-1172.	1.6	9

#	ARTICLE	IF	CITATIONS
258	Endosome to trans-Golgi network transport of Proprotein Convertase 7 is mediated by a cluster of basic amino acids and palmitoylated cysteines. <i>European Journal of Cell Biology</i> , 2017, 96, 432-439.	1.6	9
259	The FOURIER study: The profound study of Nature is the most fertile source of discovery. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 146-147.	0.4	3
261	Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 923-932.	0.6	10
262	Site-1 protease and lysosomal homeostasis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 2162-2168.	1.9	18
263	Furin as proprotein convertase and its role in normal and pathological biological processes. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2017, 11, 87-100.	0.2	3
264	Pcsk5 is required in the early cranio-cardiac mesoderm for heart development. <i>BMC Developmental Biology</i> , 2017, 17, 6.	2.1	10
265	The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels. <i>Lipids in Health and Disease</i> , 2017, 16, 119.	1.2	3
266	Mexneurin is a novel precursor of peptides in the central nervous system of rodents. <i>FEBS Letters</i> , 2017, 591, 1627-1636.	1.3	7
267	PCSK9: Regulation and Target for Drug Development for Dyslipidemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 223-244.	4.2	58
268	Effect of Alirocumab on Lipoprotein(a) Over 1.5 Years (from the Phase 3 ODYSSEY Program). <i>American Journal of Cardiology</i> , 2017, 119, 40-46.	0.7	116
269	Peptidomics of the zebrafish <i>Danio rerio</i> : In search for neuropeptides. <i>Journal of Proteomics</i> , 2017, 150, 290-296.	1.2	16
270	Pharmacological management of diabetic dyslipidemia. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 187-200.	1.3	23
271	Apelinergic System Structure and Function. , 2017, 8, 407-450.		68
272	Identification of a potential functional single nucleotide polymorphism for fatness and growth traits in the 3' untranslated region of the PCSK1 gene in chickens. <i>Journal of Animal Science</i> , 2017, 95, 4776-4786.	0.2	9
273	<i>Plasmodium berghei</i> PIMMS2 Promotes Ookinete Invasion of the <i>Anopheles gambiae</i> Mosquito Midgut. <i>Infection and Immunity</i> , 2017, 85, .	1.0	13
274	Protection against Shiga Toxins. <i>Toxins</i> , 2017, 9, 44.	1.5	51
275	Human Subtilisin Kexin Isozyme-1 (SKI-1)/Site-1 Protease (S1P) regulates cytoplasmic lipid droplet abundance: A potential target for indirect-acting anti-dengue virus agents. <i>PLoS ONE</i> , 2017, 12, e0174483.	1.1	31
276	The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. <i>Global Cardiology Science & Practice</i> , 2017, 2017, e201702.	0.3	31

#	ARTICLE	IF	CITATIONS
277	The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina. <i>Journal of Thoracic Disease</i> , 2017, 9, 1226-1233.	0.6	2
278	Compartment-Specific Biosensors Reveal a Complementary Subcellular Distribution of Bioactive Furin and PC7. <i>Cell Reports</i> , 2018, 22, 2176-2189.	2.9	16
279	Luteolin escape mutants of dengue virus map to prM and NS2B and reveal viral plasticity during maturation. <i>Antiviral Research</i> , 2018, 154, 87-96.	1.9	18
280	Diversity of Neuropeptide Cell-Cell Signaling Molecules Generated by Proteolytic Processing Revealed by Neuropeptidomics Mass Spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2018, 29, 807-816.	1.2	29
281	Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. <i>Journal of Clinical Lipidology</i> , 2018, 12, 958-965.	0.6	44
282	Inclisiran for the treatment of dyslipidemia. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 287-294.	1.9	40
283	Small Molecule Inhibitors of the PCSK9-LDLR Interaction. <i>Journal of the American Chemical Society</i> , 2018, 140, 3242-3249.	6.6	53
284	Intracellular drug delivery: Potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy. <i>Biotechnology Advances</i> , 2018, 36, 613-623.	6.0	34
285	Enzymatic sources and physio-pathological functions of soluble (pro)renin receptor. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 77-82.	1.0	16
286	The ever-expanding saga of the proprotein convertases and their roles in body homeostasis. <i>Current Opinion in Lipidology</i> , 2018, 29, 144-150.	1.2	30
287	Proteolytic Cleavage Mechanisms, Function, and Approaches for a Near-Ubiquitous Posttranslational Modification. <i>Chemical Reviews</i> , 2018, 118, 1137-1168.	23.0	145
288	Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype. <i>Journal of Biological Chemistry</i> , 2018, 293, 1875-1886.	1.6	15
289	X-ray Structures of the Proprotein Convertase Furin Bound with Substrate Analogue Inhibitors Reveal Substrate Specificity Determinants beyond the S4 Pocket. <i>Biochemistry</i> , 2018, 57, 925-934.	1.2	30
290	Pharmacogenomics of blood lipid regulation. <i>Pharmacogenomics</i> , 2018, 19, 651-665.	0.6	3
291	Black Raspberry Extract Enhances LDL Uptake in HepG2 Cells by Suppressing PCSK9 Expression to Upregulate LDLR Expression. <i>Journal of Medicinal Food</i> , 2018, 21, 560-567.	0.8	7
292	Perspectives on the discovery of NOTCH2-specific inhibitors. <i>Chemical Biology and Drug Design</i> , 2018, 91, 691-706.	1.5	6
293	Functional analysis of corin protein domains required for PCSK6-mediated activation. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 94, 31-39.	1.2	15
294	Osteopontin as a novel substrate for the proprotein convertase 5/6 (PCSK5) in bone. <i>Bone</i> , 2018, 107, 45-55.	1.4	14

#	ARTICLE	IF	CITATIONS
295	Time-course of transcriptome response to respiratory syncytial virus infection in lung epithelium cells. <i>Acta Virologica</i> , 2018, 62, 310-325.	0.3	9
296	Neuropeptides as Ligands for GPCRs. , 0, , .		5
297	Investigation on the processing and improving the cleavage efficiency of furin cleavage sites in <i>Pichia pastoris</i> . <i>Microbial Cell Factories</i> , 2018, 17, 172.	1.9	9
298	Extracellular Processing of Lysyl Oxidase-like 2 and Its Effect on Amine Oxidase Activity. <i>Biochemistry</i> , 2018, 57, 6973-6983.	1.2	27
299	Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 11250-11260.	2.9	6
300	Discovery of N-(piperidin-3-yl)-N-(pyridin-2-yl)piperidine/piperazine-1-carboxamides as small molecule inhibitors of PCSK9. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3685-3688.	1.0	11
301	The Antiviral Potential of Host Protease Inhibitors. , 2018, , 279-325.		22
302	Cleavage of the Glycoprotein of Arenaviruses. , 2018, , 47-70.		2
303	Priming Time: How Cellular Proteases Arm Coronavirus Spike Proteins. , 2018, , 71-98.		69
304	Characterization of Proprotein Convertases and Their Involvement in Virus Propagation. , 2018, , 205-248.		21
305	Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018, 1863, 991-997.	1.2	14
306	Proteolytic ectodomain shedding of membrane proteins in mammalsâ€”hardware, concepts, and recent developments. <i>EMBO Journal</i> , 2018, 37, ,	3.5	211
307	Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance. <i>Journal of Lipid Research</i> , 2018, 59, 1501-1509.	2.0	8
308	Cleavage activates Dispatched for Sonic Hedgehog ligand release. <i>ELife</i> , 2018, 7, ,	2.8	25
309	A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice. <i>Biological Chemistry</i> , 2018, 399, 1363-1374.	1.2	10
310	Reviewing Mechanistic Peptidomics in Body Fluids Focusing on Proteases. <i>Proteomics</i> , 2018, 18, e1800187.	1.3	18
311	Deciphering molecular consequences of the proprotein convertase 1/3 inhibition in macrophages for application in anti-tumour immunotherapy. <i>Journal of Biotechnology</i> , 2018, 282, 80-85.	1.9	5
312	Human brain gene expression profiles of the cathepsin V and cathepsin L cysteine proteases, with the PC1/3 and PC2 serine proteases, involved in neuropeptide production. <i>Heliyon</i> , 2018, 4, e00673.	1.4	9

#	ARTICLE	IF	CITATIONS
313	PCSK9. <i>Circulation Research</i> , 2018, 122, 1420-1438.	2.0	198
314	Furin inhibitor protects against neuronal cell death induced by activated NMDA receptors. <i>Scientific Reports</i> , 2018, 8, 5212.	1.6	19
315	Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5704-5718.	2.9	37
316	The cholesterol, fatty acid and triglyceride synthesis pathways regulated by site 1 protease (S1P) are required for efficient replication of severe fever with thrombocytopenia syndrome virus. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 631-636.	1.0	13
317	Regulation of POMC and ACTH Secretion. , 2019, , 27-37.		0
318	PCSK9 in diabetes: sweet, bitter or sour?. <i>European Heart Journal</i> , 2019, 40, 369-371.	1.0	8
319	Furin-mediated protein processing in infectious diseases and cancer. <i>Clinical and Translational Immunology</i> , 2019, 8, e1073.	1.7	231
320	Furin-mediated cleavage of LRP1 and increase in ICD of LRP1 after cerebral ischemia and after exposure of cultured neurons to NMDA. <i>Scientific Reports</i> , 2019, 9, 11782.	1.6	14
321	<i>Drosophila</i> carboxypeptidase D (SILVER) is a key enzyme in neuropeptide processing required to maintain locomotor activity levels and survival rate. <i>European Journal of Neuroscience</i> , 2019, 50, 3502-3519.	1.2	5
322	A novel cell-based sensor detecting the activity of individual basic proprotein convertases. <i>FEBS Journal</i> , 2019, 286, 4597-4620.	2.2	4
323	C-terminal proteolysis of the collagen VI $\alpha 3$ chain by BMP-1 and proprotein convertase(s) releases endotrophin in fragments of different sizes. <i>Journal of Biological Chemistry</i> , 2019, 294, 13769-13780.	1.6	38
324	Sulfated plant peptide hormones. <i>Journal of Experimental Botany</i> , 2019, 70, 4267-4277.	2.4	67
325	N-Glycosylation is required for secretion of the precursor to brain-derived neurotrophic factor (proBDNF) carrying sulfated LacdiNAc structures. <i>Journal of Biological Chemistry</i> , 2019, 294, 16816-16830.	1.6	17
326	The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process " is there a link?. <i>Kardiochirurgia i Torakochirurgia Polska</i> , 2019, 16, 128-132.	0.1	2
327	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. <i>Cardiovascular Research</i> , 2019, 115, 510-518.	1.8	63
328	Proteases facilitate the endosomal escape of porcine epidemic diarrhea virus during entry into host cells. <i>Virus Research</i> , 2019, 272, 197730.	1.1	6
329	Effect of Sleeve Gastrectomy on Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Content and Lipid Metabolism in the Blood Plasma and Liver of Obese Wistar Rats. <i>Nutrients</i> , 2019, 11, 2174.	1.7	3
330	The Proteolytic Regulation of Virus Cell Entry by Furin and Other Proprotein Convertases. <i>Viruses</i> , 2019, 11, 837.	1.5	131

#	ARTICLE	IF	CITATIONS
331	A semisynthetic fluorescent protein assembly-based FRET probe for real-time profiling of cell membrane protease functions <i>in situ</i> . <i>Chemical Communications</i> , 2019, 55, 2218-2221.	2.2	13
332	Design, Synthesis, and Characterization of Macrocyclic Inhibitors of the Proprotein Convertase Furin. <i>ChemMedChem</i> , 2019, 14, 673-685.	1.6	27
333	HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin. <i>Cell Death and Differentiation</i> , 2019, 26, 1942-1954.	5.0	11
334	Near-Infrared Fluorescent Furin Probe for Revealing the Role of Furin in Cellular Carcinogenesis and Specific Cancer Imaging. <i>Analytical Chemistry</i> , 2019, 91, 9682-9689.	3.2	28
335	Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality. <i>Journal of Internal Medicine</i> , 2019, 286, 553-561.	2.7	35
336	Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2814.	1.8	9
337	Guanylate-Binding Proteins 2 and 5 Exert Broad Antiviral Activity by Inhibiting Furin-Mediated Processing of Viral Envelope Proteins. <i>Cell Reports</i> , 2019, 27, 2092-2104.e10.	2.9	112
339	Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases. <i>Toxicology and Applied Pharmacology</i> , 2019, 370, 170-177.	1.3	18
340	Specific and Selective Inhibitors of Proprotein Convertases Engineered by Transferring Serpin B8 Reactive-Site and Exosite Determinants of Reactivity to the Serpin I \pm 1PDX. <i>Biochemistry</i> , 2019, 58, 1679-1688.	1.2	8
341	Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, promotes angiogenesis in vitro. <i>Canadian Journal of Physiology and Pharmacology</i> , 2019, 97, 352-358.	0.7	7
342	BacMam production and crystal structure of nonglycosylated apo human furin at 1.89 Å resolution. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2019, 75, 239-245.	0.4	8
343	Transcriptome analysis reveals the activation of neuroendocrine-immune system in shrimp hemocytes at the early stage of WSSV infection. <i>BMC Genomics</i> , 2019, 20, 247.	1.2	32
344	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 930-949.	0.8	64
345	A New Case of PCSK1 Pathogenic Variant With Congenital Proprotein Convertase 1/3 Deficiency and Literature Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 985-993.	1.8	39
346	Heterogeneous Expression of Proinsulin Processing Enzymes in Beta Cells of Non-diabetic and Type 2 Diabetic Humans. <i>Journal of Histochemistry and Cytochemistry</i> , 2019, 67, 385-400.	1.3	13
347	Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug. <i>Scientific Reports</i> , 2019, 9, 2118.	1.6	11
348	DNA nanodevices map enzymatic activity in organelles. <i>Nature Nanotechnology</i> , 2019, 14, 252-259.	15.6	72
349	Cholesterol and stroke: role of PCSK9 inhibitors. <i>Neurologia (English Edition)</i> , 2019, 34, 198-203.	0.2	0

#	ARTICLE	IF	CITATIONS
350	Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome. <i>Coronary Artery Disease</i> , 2019, 30, 285-290.	0.3	6
351	Furin-mediated intracellular self-assembly of olsalazine nanoparticles for enhanced magnetic resonance imaging and tumour therapy. <i>Nature Materials</i> , 2019, 18, 1376-1383.	13.3	164
352	Serum PCSK6 and corin levels are not associated with cardiovascular outcomes in patients undergoing coronary angiography. <i>PLoS ONE</i> , 2019, 14, e0226129.	1.1	8
353	Small molecules as inhibitors of PCSK9: Current status and future challenges. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 212-233.	2.6	58
354	Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics. <i>Molecular Therapy</i> , 2019, 27, 188-199.	3.7	23
355	Proapelin is processed extracellularly in a cell line-dependent manner with clear modulation by proprotein convertases. <i>Amino Acids</i> , 2019, 51, 395-405.	1.2	6
356	Proteolytic Activation of Bmps: Analysis of Cleavage in <i>Xenopus</i> Oocytes and Embryos. <i>Methods in Molecular Biology</i> , 2019, 1891, 115-133.	0.4	1
357	FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 387-401.	1.1	51
358	Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 199.	1.1	47
359	PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides. <i>International Journal of Molecular Sciences</i> , 2019, 20, 245.	1.8	32
360	Inhibiting PCSK9 " biology beyond LDL control. <i>Nature Reviews Endocrinology</i> , 2019, 15, 52-62.	4.3	96
361	Integrins $\alpha_5\beta_1$ and $\alpha_6\beta_1$ Mediate IL-4-induced Collective Migration in Human Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 420-433.	1.4	19
362	Spatiotemporal-controlled Reporter for Cell Surface Proteolytic Enzyme Activity Visualization. <i>ChemBioChem</i> , 2019, 20, 561-567.	1.3	6
363	Cell-Cell Interactions in Ovarian Follicles: Role of TGF- β Superfamily Members. , 2019, , 107-125.		11
364	Colesterol e ictus: papel de los inhibidores de la proproteína convertasa subtilisina/kexina tipo 9. <i>Neurología</i> , 2019, 34, 198-203.	0.3	3
365	Functional analysis of natural PCSK9 mutants in modern and archaic humans. <i>FEBS Journal</i> , 2020, 287, 515-528.	2.2	8
366	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. <i>Revista Clínica Española</i> , 2020, 220, 374-382.	0.3	0
367	Mechanisms and regulation of cholesterol homeostasis. <i>Nature Reviews Molecular Cell Biology</i> , 2020, 21, 225-245.	16.1	899

#	ARTICLE	IF	CITATIONS
368	Inclisiran – New hope in the management of lipid disorders?. <i>Journal of Clinical Lipidology</i> , 2020, 14, 16-27.	0.6	80
369	PCSK6 Is a Key Protease in the Control of Smooth Muscle Cell Function in Vascular Remodeling. <i>Circulation Research</i> , 2020, 126, 571-585.	2.0	38
370	EGF-A peptides: A promising strategy for PCSK9 inhibition. <i>Atherosclerosis</i> , 2020, 292, 204-206.	0.4	8
371	Human Islets Contain a Beta Cell Type That Expresses Proinsulin But Not the Enzyme That Converts the Precursor to Insulin. <i>Journal of Histochemistry and Cytochemistry</i> , 2020, 68, 691-702.	1.3	1
372	Drug Weaponry to Fight Against SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 204.	1.6	2
373	Similar sequences but dissimilar biological functions of GDF11 and myostatin. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1673-1693.	3.2	21
374	Targeting Proteases for Treating COVID-19. <i>Journal of Proteome Research</i> , 2020, 19, 4316-4326.	1.8	68
375	Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. <i>Cell Reports</i> , 2020, 33, 108254.	2.9	195
376	BMP2 increases the production of BDNF through the upregulation of proBDNF and furin expression in human granulosa lutein cells. <i>FASEB Journal</i> , 2020, 34, 16129-16143.	0.2	12
377	Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular Complications. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1103-1108.	0.3	15
378	Cleavage of the soluble (pro)renin receptor (sATP6AP2) in the placenta. <i>Placenta</i> , 2020, 101, 49-56.	0.7	8
379	Peptide and peptide-based inhibitors of SARS-CoV-2 entry. <i>Advanced Drug Delivery Reviews</i> , 2020, 167, 47-65.	6.6	132
380	Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 20753-20763.	3.3	45
381	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 4-33.	6.6	113
382	A Pilot Screen of a Novel Peptide Hormone Library Identified Candidate GPR83 Ligands. <i>SLAS Discovery</i> , 2020, 25, 1047-1063.	1.4	11
383	A comparative genomics study of neuropeptide genes in the cnidarian subclasses Hexacorallia and Ceriantharia. <i>BMC Genomics</i> , 2020, 21, 666.	1.2	18
384	Advances in the development of fluorescence probes for cell plasma membrane imaging. <i>TrAC - Trends in Analytical Chemistry</i> , 2020, 133, 116092.	5.8	59
385	Furin – Instructed Intracellular Gold Nanoparticle Aggregation for Tumor Photothermal Therapy. <i>Advanced Functional Materials</i> , 2020, 30, 2001566.	7.8	71

#	ARTICLE	IF	CITATIONS
386	Increased FURIN expression in rheumatoid arthritis patients and its anti-inflammatory effect. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23530.	0.9	10
387	Shedding of cancer susceptibility candidate 4 by the convertases PC7/furin unravels a novel secretory protein implicated in cancer progression. <i>Cell Death and Disease</i> , 2020, 11, 665.	2.7	10
388	Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. <i>Cells</i> , 2020, 9, 2638.	1.8	138
389	COVID-19: Targeting Proteases in Viral Invasion and Host Immune Response. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 215.	1.6	42
390	Inhibitors of neuropeptide peptidases engaged in pain and drug dependence. <i>Neuropharmacology</i> , 2020, 175, 108137.	2.0	5
391	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders. <i>Frontiers in Neuroscience</i> , 2020, 14, 609.	1.4	45
392	Extra Virgin Olive Oil Phenol Extracts Exert Hypocholesterolemic Effects through the Modulation of the LDLR Pathway: In Vitro and Cellular Mechanism of Action Elucidation. <i>Nutrients</i> , 2020, 12, 1723.	1.7	30
393	The motif EXEXXL in the cytosolic tail of the secretory human proprotein convertase PC7 regulates its trafficking and cleavage activity. <i>Journal of Biological Chemistry</i> , 2020, 295, 2068-2083.	1.6	5
394	Human and mouse activin genes: Divergent expression of activin A protein variants and identification of a novel heparan sulfate-binding domain in activin B. <i>PLoS ONE</i> , 2020, 15, e0229254.	1.1	1
395	The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. <i>Antiviral Research</i> , 2020, 176, 104742.	1.9	1,450
396	An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 531-539.	0.9	17
397	Design of Organo-Peptides As Bipartite PCSK9 Antagonists. <i>ACS Chemical Biology</i> , 2020, 15, 425-436.	1.6	13
398	Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 403-414.	2.5	3
399	TGF- β 1 Increases GDNF Production by Upregulating the Expression of GDNF and Furin in Human Granulosa-Lutein Cells. <i>Cells</i> , 2020, 9, 185.	1.8	13
400	Proprotein convertase 7 (PCSK7) reduces apoA-II levels. <i>FEBS Journal</i> , 2020, 287, 3565-3578.	2.2	13
401	Engineering the Plant Secretory Pathway for the Production of Next-Generation Pharmaceuticals. <i>Trends in Biotechnology</i> , 2020, 38, 1034-1044.	4.9	43
402	Protease propeptide structures, mechanisms of activation, and functions. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2020, 55, 111-165.	2.3	37
403	POST1/C12ORF49 regulates the SREBP pathway by promoting site-1 protease maturation. <i>Protein and Cell</i> , 2021, 12, 279-296.	4.8	31

#	ARTICLE	IF	CITATIONS
404	Loss of <i>Furin</i> in β -Cells Induces an mTORC1-ATF4 Anabolic Pathway That Leads to β -Cell Dysfunction. <i>Diabetes</i> , 2021, 70, 492-503.	0.3	20
405	Baicalein inhibits <i>FURIN</i> - <i>MT1</i> - <i>MMP</i> -mediated invasion of ectopic endometrial stromal cells in endometriosis possibly by reducing the secretion of <i>TGFB1</i> . <i>American Journal of Reproductive Immunology</i> , 2021, 85, e13344.	1.2	5
406	Activation of proprotein convertase in the mouse habenula causes depressive-like behaviors through remodeling of extracellular matrix. <i>Neuropsychopharmacology</i> , 2021, 46, 442-454.	2.8	5
407	FH through the retrospectoscope. <i>Journal of Lipid Research</i> , 2021, 62, 100036.	2.0	5
408	Research Progress on the Relationship between PCSK9 and Development of Tumor. <i>Medical Diagnosis</i> , 2021, 11, 42-46.	0.0	0
409	Structural basis of FGF23 hormone signaling. , 2021, , 299-318.		0
410	The interactions of folate with the enzyme furin: a computational study. <i>RSC Advances</i> , 2021, 11, 23815-23824.	1.7	6
412	Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 1275-1284.	0.9	4
413	Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 660.	1.8	15
414	The Basicity Makes the Difference: Improved Canavanine-Derived Inhibitors of the Proprotein Convertase Furin. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 426-432.	1.3	11
415	Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 365-372.	1.3	7
416	Changes in PCSK 9 and apolipoprotein B100 in Niemann-Pick disease after enzyme replacement therapy with olipudase alfa. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 107.	1.2	9
417	Identifying Receptors for Neuropeptides and Peptide Hormones: Challenges and Recent Progress. <i>ACS Chemical Biology</i> , 2021, 16, 251-263.	1.6	16
418	Potential Differences in Cleavage of the S Protein and Type 1 Interferon Together Control Human Coronavirus Infection, Propagation, and Neuropathology within the Central Nervous System. <i>Journal of Virology</i> , 2021, 95, .	1.5	14
419	The Tumor Proteolytic Landscape: A Challenging Frontier in Cancer Diagnosis and Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2514.	1.8	35
420	The Double Edge Sword of Testosterone's Role in the COVID-19 Pandemic. <i>Frontiers in Endocrinology</i> , 2021, 12, 607179.	1.5	27
421	An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndrome-Coronavirus. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 637550.	1.6	8
422	Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. <i>Nature Medicine</i> , 2021, 27, 546-559.	15.2	261

#	ARTICLE	IF	CITATIONS
423	Pan-Cancer Analysis of FURIN as a Potential Prognostic and Immunological Biomarker. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 648402.	1.6	14
426	The Role of Proprotein Convertases in the Regulation of the Function of Immune Cells in the Oncoimmune Response. <i>Frontiers in Immunology</i> , 2021, 12, 667850.	2.2	14
427	Proprotein Convertase Is the Highest-Level Activator of the Alternative Complement Pathway in the Blood. <i>Journal of Immunology</i> , 2021, 206, 2198-2205.	0.4	12
428	Furin is involved in uterine activation for labor. <i>FASEB Journal</i> , 2021, 35, e21565.	0.2	3
430	Association of baseline as well as change in lipid levels with the risk of cardiovascular diseases and all-cause deaths. <i>Scientific Reports</i> , 2021, 11, 7381.	1.6	11
431	Novel Homozygous Inactivating Mutation in the PCSK1 Gene in an Infant with Congenital Malabsorptive Diarrhea. <i>Genes</i> , 2021, 12, 710.	1.0	9
432	Multifactorial Traits of SARS-CoV-2 Cell Entry Related to Diverse Host Proteases and Proteins. <i>Biomolecules and Therapeutics</i> , 2021, 29, 249-262.	1.1	2
433	Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy. <i>Current Medicinal Chemistry</i> , 2022, 29, 635-665.	1.2	11
434	PCSK9 Biology and Its Role in Atherothrombosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5880.	1.8	70
436	Collagen VI as a driver and disease biomarker in human fibrosis. <i>FEBS Journal</i> , 2022, 289, 3603-3629.	2.2	37
437	Skutki hamowania funkcji PCSK9 w obrã™bie wybranych tkanek[*]. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021, 75, 385-397.	0.1	2
438	Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. <i>Atherosclerosis</i> , 2021, 326, 47-55.	0.4	18
439	In Vivo Analysis of the Contribution of Proprotein Convertases to the Processing of FGF23. <i>Frontiers in Endocrinology</i> , 2021, 12, 690681.	1.5	8
440	How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread?. <i>Viruses</i> , 2021, 13, 1229.	1.5	18
442	Proprotein convertase subtilisin/kexin type 9 regulates the production of acuteâ€phase reactants from the liver. <i>Liver International</i> , 2021, 41, 2511-2522.	1.9	7
443	Label-Free Electrochemical Test of Protease Interaction with a Peptide Substrate Modified Gold Electrode. <i>Chemosensors</i> , 2021, 9, 199.	1.8	4
444	FAM20C Overview: Classic and Novel Targets, Pathogenic Variants and Raine Syndrome Phenotypes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8039.	1.8	11
445	Effect of clinical isolate or cleavage site mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cellâ€cell fusion. <i>Journal of Biological Chemistry</i> , 2021, 297, 100902.	1.6	17

#	ARTICLE	IF	CITATIONS
447	PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. <i>Biomedicines</i> , 2021, 9, 793.	1.4	27
449	Why All the Fury over Furin?. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2747-2784.	2.9	23
451	Identification and characterization of Furins in larvae of <i>Protaetia brevitarsis seulensis</i> (Kolbe) (Coleoptera: Cetoniidae). <i>Journal of Asia-Pacific Entomology</i> , 2021, 24, 824-831.	0.4	0
452	Proteolytic processing of secretory pathway kinase Fam20C by site-1 protease promotes biomineralization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	8
453	OFF-State-Specific Inhibition of the Proprotein Convertase Furin. <i>ACS Chemical Biology</i> , 2021, 16, 1692-1700.	1.6	10
454	Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 708039.	1.3	14
455	PCSK9 and cancer: Rethinking the link. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111758.	2.5	41
456	AI-Generated Lifetime Probes for Precise Furin Quantification and Identification of Cell Subtypes. <i>Advanced Materials</i> , 2021, 33, e2104615.	11.1	15
457	Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2. <i>Journal of Controlled Release</i> , 2021, 337, 258-284.	4.8	12
458	Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin. <i>Journal of Biological Chemistry</i> , 2021, 297, 101177.	1.6	15
459	Inclisiran in lipid management: A Literature overview and future perspectives. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112227.	2.5	27
460	Semisyntetic biflavonoid Morelloflavone-7,4,7,3,4-penta-O-butanoyl is a more potent inhibitor of Proprotein Convertases Subtilisin/Kexin PC1/3 than Kex2 and Furin. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 130016.	1.1	1
461	Furin cleavage sites in the spike proteins of bat and rodent coronaviruses: Implications for virus evolution and zoonotic transfer from rodent species. <i>One Health</i> , 2021, 13, 100282.	1.5	19
462	Tools and Methods to Study the Human Glycome. , 2021, , 416-431.		0
464	PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection. <i>Methods in Molecular Biology</i> , 2020, 2204, 133-143.	0.4	1
465	Knockdown Strategies for the Study of Proprotein Convertases and Proliferation in Prostate Cancer Cells. <i>Methods in Molecular Biology</i> , 2014, 1103, 67-82.	0.4	6
466	An Overview of the Crystallized Structures of the SARS-CoV-2. <i>Protein Journal</i> , 2020, 39, 600-618.	0.7	32
467	Inhibidores de PCSK9: ratificaci3n del papel del colesterol LDL en prevenci3n cardiovascular. ¿Hacia la convergencia en las guÍas de prevenci3n europeas y norteamericanas?. <i>Revista Clinica Espanola</i> , 2020, 220, 374-382.	0.2	5

#	ARTICLE	IF	CITATIONS
468	Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering. <i>Biochemical Society Transactions</i> , 2020, 48, 1323-1336.	1.6	7
472	SORCS1 is necessary for normal insulin secretory granule biogenesis in metabolically stressed β^2 cells. <i>Journal of Clinical Investigation</i> , 2014, 124, 4240-4256.	3.9	53
473	Proprotein convertase furin regulates osteocalcin and bone endocrine function. <i>Journal of Clinical Investigation</i> , 2017, 127, 4104-4117.	3.9	55
474	NRP1 transport of cancer therapeutics mediated by tumor-penetrating peptides. <i>Drugs of the Future</i> , 2017, 42, 0095.	0.0	12
475	Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation. <i>PLoS ONE</i> , 2012, 7, e41865.	1.1	98
476	Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels. <i>PLoS ONE</i> , 2013, 8, e60095.	1.1	54
477	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1). <i>PLoS ONE</i> , 2013, 8, e64145.	1.1	183
478	A Novel Two-Tag System for Monitoring Transport and Cleavage through the Classical Secretory Pathway – Adaptation to HIV Envelope Processing. <i>PLoS ONE</i> , 2013, 8, e68835.	1.1	5
479	PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation. <i>PLoS ONE</i> , 2013, 8, e72113.	1.1	20
480	Furin Is the Major Proprotein Convertase Required for KISS1-to-Kisspeptin Processing. <i>PLoS ONE</i> , 2014, 9, e84958.	1.1	21
481	Alpha-Lipoic Acid Reduces LDL-Particle Number and PCSK9 Concentrations in High-Fat Fed Obese Zucker Rats. <i>PLoS ONE</i> , 2014, 9, e90863.	1.1	34
482	Distinct Interactions with Cellular E-Cadherin of the Two Virulent Metalloproteinases Encoded by a <i>Bacteroides fragilis</i> Pathogenicity Island. <i>PLoS ONE</i> , 2014, 9, e113896.	1.1	35
483	A Selective Irreversible Inhibitor of Furin Does Not Prevent <i>Pseudomonas Aeruginosa</i> Exotoxin A-Induced Airway Epithelial Cytotoxicity. <i>PLoS ONE</i> , 2016, 11, e0159868.	1.1	10
484	Evidence that Processing of the Severe Fever with Thrombocytopenia Syndrome Virus Gn/Gc Polyprotein Is Critical for Viral Infectivity and Requires an Internal Gc Signal Peptide. <i>PLoS ONE</i> , 2016, 11, e0166013.	1.1	26
485	Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection. <i>PLoS ONE</i> , 2018, 13, e0191983.	1.1	10
486	Synthesis and investigation of the derivatives of amidinohydrazone-related aromatic compounds as furin inhibitors. <i>Ukrainian Biochemical Journal</i> , 2017, 89, 3-12.	0.1	2
487	The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology. <i>European Cardiology Review</i> , 2014, 9, 65.	0.7	6
489	Myeloid cell expressed proprotein convertase FURIN attenuates inflammation. <i>Oncotarget</i> , 2016, 7, 54392-54404.	0.8	30

#	ARTICLE	IF	CITATIONS
490	The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells. <i>Oncotarget</i> , 2016, 7, 76743-76755.	0.8	5
491	Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 80826-80840.	0.8	22
492	PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation. <i>Oncotarget</i> , 2015, 6, 3680-3693.	0.8	35
493	Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus. <i>Annals of Translational Medicine</i> , 2018, 6, 130-130.	0.7	8
494	Epidemiological and Transmission Patterns of Pregnant Women with 2019 Coronavirus Disease in China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	12
495	Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease. <i>Current Genomics</i> , 2013, 14, 453-467.	0.7	51
496	Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis. <i>Current Drug Targets</i> , 2019, 20, 1029-1040.	1.0	2
497	Radiotherapy-associated Furin Expression and Tumor Invasiveness in Recurrent Laryngeal Cancer. <i>Anticancer Research</i> , 2016, 36, 5117-5126.	0.5	14
498	PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD). <i>Advanced Pharmaceutical Bulletin</i> , 2020, 10, 502-511.	0.6	15
499	Expression of paired basic amino acid-cleaving enzyme 4 (PACE4) correlated with prognosis in non-small cell lung cancer (NSCLC) patients. <i>Journal of Thoracic Disease</i> , 2015, 7, 850-60.	0.6	11
500	New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?. <i>World Journal of Hepatology</i> , 2013, 5, 676.	0.8	13
501	An Update on the Role of PCSK9 in Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 909-918.	0.9	47
502	Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy. <i>Drugs in Context</i> , 2017, 6, 1-7.	1.0	16
503	The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer. <i>Journal of Lipid Research</i> , 2021, 62, 100130.	2.0	32
504	PCSK9 Axis-Targeting Pseurotin A as a Novel Prostate Cancer Recurrence Suppressor Lead. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1771-1781.	2.5	12
505	Structural characteristics of Heparan sulfate required for the binding with the virus processing Enzyme Furin. <i>Glycoconjugate Journal</i> , 2022, 39, 315-325.	1.4	3
507	The Multifaceted Biology of PCSK9. <i>Endocrine Reviews</i> , 2022, 43, 558-582.	8.9	75
508	Prohormone Convertasesâˆ†. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
509	Statins and PCSK9 Inhibitors: Defining the Correct Patients. , 2015, , 99-117.		1
510	Neuroendocrine Peptide Processing α †. , 2017, , .		0
511	Influence of organic solvents on the furin activity. Ukrainian Biochemical Journal, 2018, 90, 28-33.	0.1	0
514	PCSK9 Inhibition with Evolocumab Reaching Physiologic LDL-C Levels for Reducing Atherosclerotic Burden and Cardiovascular Disease-The Full Landscape. Frontiers in Cardiovascular Drug Discovery, 2019, , 148-185.	0.0	0
515	1,3-Oxazol-4-ylphosphonium salts as new non-peptide inhibitors of furin. Ukrainian Biochemical Journal, 2019, 91, 5-16.	0.1	0
516	Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis. Russian Journal of Cardiology, 2019, , 52-55.	0.4	0
517	Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. Journal of Atherosclerosis and Thrombosis, 2020, 29, .	0.9	4
518	Marked increase in tumor transfection with a truncated branched polymer. Journal of Gene Medicine, 2022, 24, e3396.	1.4	4
519	Molecular evolution of PCSK family: Analysis of natural selection rate and gene loss. PLoS ONE, 2021, 16, e0259085.	1.1	2
520	Mouse Models of Human Proprotein Convertase Insufficiency. Endocrine Reviews, 2021, 42, 259-294.	8.9	12
521	Site-1 and site-2 proteases: A team of two in regulated proteolysis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119138.	1.9	12
522	Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity. PLoS ONE, 2021, 16, e0259353.	1.1	1
526	O tratamento da hipercolesterolemia familiar com os inibidores de PCSK9: uma revisÃ£o integrativa. Research, Society and Development, 2021, 10, e233101523018.	0.0	0
527	An evolutionary genomics view on neuropeptide genes in Hydrozoa and Endocnidozoa (Myxozoa). BMC Genomics, 2021, 22, 862.	1.2	4
528	Spike Protein Cleavage-Activation Mediated by the SARS-CoV-2 P681R Mutation: A Case-Study From Its First Appearance in Variant of Interest (VOI) A.23.1 Identified in Uganda. SSRN Electronic Journal, 0, , .	0.4	8
529	Proprotein Convertases. , 2021, , 1263-1267.		0
531	Small disulfide loops in peptide hormones mediate self-aggregation and secretory granule sorting. Life Science Alliance, 2022, 5, e202101279.	1.3	2
532	Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike. IScience, 2022, 25, 103589.	1.9	134

#	ARTICLE	IF	CITATIONS
533	Activation by cleavage of the epithelial Na ⁺ channel α and β subunits independently coevolved with the vertebrate terrestrial migration. <i>ELife</i> , 2022, 11, .	2.8	5
534	Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia. <i>Drug Discovery Today</i> , 2022, 27, 1332-1349.	3.2	25
535	Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus. <i>Vitamins and Hormones</i> , 2022, 118, 457-478.	0.7	7
536	Protein and peptide engineering for chemical exchange saturation transfer imaging in the age of synthetic biology. <i>NMR in Biomedicine</i> , 2023, 36, e4712.	1.6	8
537	Theta-Defensins to Counter COVID-19 as Furin Inhibitors: In Silico Efficiency Prediction and Novel Compound Design. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-15.	0.7	8
538	Design, Synthesis, and Antiviral activity of 1,2,3,4-Tetrahydropyrimidine derivatives acting as novel entry inhibitors to target at α Phe43 cavity of HIV-1 gp120. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 52, 116526.	1.4	6
539	A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease. <i>Cell Chemical Biology</i> , 2022, 29, 947-957.e8.	2.5	11
540	Annotated Protein Database Using Known Cleavage Sites for Rapid Detection of Secreted Proteins. <i>Journal of Proteome Research</i> , 2022, 21, 965-974.	1.8	1
541	The relevant information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the five-question approach (when, where, what, why, and how) and its impact on the environment. <i>Environmental Science and Pollution Research</i> , 2023, 30, 61430-61454.	2.7	6
542	The Path to Therapeutic Furin Inhibitors: From Yeast Pheromones to SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3435.	1.8	6
543	The G209R mutant mouse as a model for human PCSK1 polyendocrinopathy. <i>Endocrinology</i> , 2022, , .	1.4	0
544	Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity. <i>Journal of Virology</i> , 2022, 96, e0012822.	1.5	64
545	Insight into the Evolving Role of PCSK9. <i>Metabolites</i> , 2022, 12, 256.	1.3	21
546	Dichlorophenylpyridine-Based Molecules Inhibit Furin through an Induced-Fit Mechanism. <i>ACS Chemical Biology</i> , 2022, 17, 816-821.	1.6	7
547	A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses. <i>Vaccines</i> , 2021, 9, 1492.	2.1	2
550	Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management.. <i>EXCLI Journal</i> , 2022, 21, 47-76.	0.5	7
551	In vitro characterization of the furin inhibitor MI-1851: Albumin binding, interaction with cytochrome P450 enzymes and cytotoxicity. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113124.	2.5	6
552	A Comprehensive Review of PCSK9 Inhibitors. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842211001.	1.0	27

#	ARTICLE	IF	CITATIONS
553	Therapeutics of platelet-derived growth factor and signaling in different organs. , 2022, , 671-688.		1
555	The Role of Proprotein Convertases in Upper Airway Remodeling. <i>Molecules and Cells</i> , 2022, 45, 353-361.	1.0	1
556	Identification of novel non-HFE mutations in Chinese patients with hereditary hemochromatosis. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, .	1.2	3
557	Calcitonin gene-related peptide: An intra-articular therapeutic target for TMJ disorders. <i>Clinical and Experimental Dental Research</i> , 0, , .	0.8	2
558	Post-Transcriptional Effects of miRNAs on PCSK7 Expression and Function: miR-125a-5p, miR-143-3p, and miR-409-3p as Negative Regulators. <i>Metabolites</i> , 2022, 12, 588.	1.3	2
559	Furin extracellularly cleaves secreted PTEN ^{Δ1/2} to generate C-terminal fragment with a tumor-suppressive role. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	4
560	Spike Protein Cleavage-Activation in the Context of the SARS-CoV-2 P681R Mutation: an Analysis from Its First Appearance in Lineage A.23.1 Identified in Uganda. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	20
561	Dysregulation of Neuropeptide and Tau Peptide Signatures in Human Alzheimer's Disease Brain. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1992-2005.	1.7	13
562	Proprotein Convertases and the Complement System. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
563	Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond. <i>Current Atherosclerosis Reports</i> , 2022, 24, 821-830.	2.0	29
564	PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: Role of hepatic cholesterol. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159217.	1.2	4
565	An Arginine-Rich Motif in the ORF2 capsid protein regulates the hepatitis E virus lifecycle and interactions with the host cell. <i>PLoS Pathogens</i> , 2022, 18, e1010798.	2.1	6
566	The emerging role of furin in neurodegenerative and neuropsychiatric diseases. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	19
567	Design, synthesis, and characterization of novel fluorogenic substrates of the proprotein convertases furin, PC1/3, PC2, PC5/6, and PC7. <i>Analytical Biochemistry</i> , 2022, , 114836.	1.1	0
568	Treatment of ovarian cancer with modified anthrax toxin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	0
569	Immunocytochemistry of phospholipase D1 and D2 in cultured cells. <i>Biochemical and Biophysical Research Communications</i> , 2022, 625, 161-166.	1.0	3
570	Activated aggregation strategies to construct size-increasing nanoparticles for cancer therapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	3.3	3
571	Energy Homeostasis Gene Nucleotide Variants and Survival of Hemodialysis Patients—A Genetic Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 5477.	1.0	1

#	ARTICLE	IF	CITATIONS
572	Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2022, 12, e061884.	0.8	0
573	Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
574	Review: The evolution of peptidergic signaling in Cnidaria and Placozoa, including a comparison with Bilateria. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	8
575	The proprotein convertase furin regulates the development of thymic epithelial cells to ensure central immune tolerance. <i>IScience</i> , 2022, 25, 105233.	1.9	2
576	Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
577	Proprotein convertase subtilisin/kexin type 9 genetic screening using the vervet (<i>Chlorocebus</i>) Tj ETQq1 1 0.784314 rgBT ₁ /Overlook	0.3	1
578	Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13429.	1.8	0
579	PCSK9 pathway-noncoding RNAs crosstalk: Emerging opportunities for novel therapeutic approaches in inflammatory atherosclerosis. <i>International Immunopharmacology</i> , 2022, 113, 109318.	1.7	4
580	Abnormal Expression of an Insulin Synthesizing Enzyme in Islets of Adult Autoantibody Positive Donors. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 695-706.	1.3	2
581	Regulated Proteolysis of Signaling Molecules: The Proprotein Convertases. , 2016, , 732-745.		0
582	Improving bone morphogenetic protein (BMP) production in CHO cells through understanding of BMP synthesis, signaling and endocytosis. <i>Biotechnology Advances</i> , 2023, 62, 108080.	6.0	1
583	Unravelling the neuropeptidome of the ornate spiny lobster <i>Panulirus ornatus</i> : A focus on peptide hormones and their processing enzymes expressed in the reproductive tissues. <i>General and Comparative Endocrinology</i> , 2023, 332, 114183.	0.8	0
584	Proprotein convertases regulate trafficking and maturation of key proteins within the secretory pathway. <i>Advances in Protein Chemistry and Structural Biology</i> , 2023, , 1-54.	1.0	2
585	Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 15513-15539.	2.9	17
586	PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and their Future Perspectives. <i>Current Molecular Pharmacology</i> , 2022, 16, .	0.7	0
587	PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity. <i>Cells</i> , 2022, 11, 4132.	1.8	5
589	Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator. <i>Cancers</i> , 2023, 15, 241.	1.7	1
590	SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2. <i>Viruses</i> , 2023, 15, 360.	1.5	3

#	ARTICLE	IF	CITATIONS
591	Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, 149, 105155.	2.9	9
592	The proprotein convertase SKI-1/S1P is a critical host factor for Nairobi sheep disease virus infectivity. <i>Virus Research</i> , 2023, 329, 199099.	1.1	1
594	Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice. <i>Molecules</i> , 2023, 28, 1460.	1.7	2
597	Overexpression of the proprotein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through <sc>RAF</sc>/<sc>MEK</sc> signaling. <i>Molecular Oncology</i> , 2023, 17, 1324-1342.	2.1	2
598	Famsin, a novel gut-secreted hormone, contributes to metabolic adaptations to fasting via binding to its receptor OLFR796. <i>Cell Research</i> , 2023, 33, 273-287.	5.7	1
599	SARS-CoV-2 S Mutations: A Lesson from the Viral World to Understand How Human Furin Works. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4791.	1.8	2
600	Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	4
601	Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry. <i>ACS Medicinal Chemistry Letters</i> , 2023, 14, 458-465.	1.3	1
602	Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes. <i>MAÅ¼narodnij EndokrinologÅ¼nij Å½urnal</i> , 2023, 19, 53-64.	0.1	0
603	Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. <i>Marine Drugs</i> , 2023, 21, 215.	2.2	1
605	FURIN regulates cytotoxic Tâ€¦lymphocyte effector function and memory cell transition in mice. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	0
641	Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, .	7.1	1